BMO Capital Starts C4 Therapeutics (CCCC) at Outperform

March 31, 2021 1:40 AM EDT
Get Alerts CCCC Hot Sheet
Price: $32.55 --0%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 16 | Down: 18 | New: 67
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

BMO Capital analyst Matthew Luchini initiates coverage on C4 Therapeutics (NASDAQ: CCCC) with a Outperform rating and a price target of $55.00.

The analyst comments "C4 is a clinical-stage biotech company developing protein degraders for the treatment of cancer and neurological disorders. We believe early disease model data from lead program CFT7455 suggests a better clinical profile than the blockbuster IMiDs in multiple myeloma and lymphoma. We believe C4 has significant platform potential given ability to develop both monofunctional and bifunctional degraders. A focus on validated targets helps de-risk development, while three collaborations (Roche, Biogen, Calico) provide external validation and non-dilutive financing."

For an analyst ratings summary and ratings history on C4 Therapeutics click here. For more ratings news on C4 Therapeutics click here.

Shares of C4 Therapeutics closed at $32.90 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage

Related Entities

BMO Capital